Medicus Pharma reported that independent clinical validation by Dr. Babar Rao confirms the Phase 2 SkinJect trial achieved an 80% overall response rate in treating nodular basal cell carcinoma, a common non-melanoma skin cancer. The study showed 73% clinical clearance, suggesting many patients could avoid immediate surgery, making SkinJect a promising non-surgical treatment alternative. The 200µg dose was identified as the lead regimen for further development, with plans to continue regulatory engagement and additional trials. This advancement could benefit patients with limited surgical access or high lesion burdens, including those with Gorlin Syndrome.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Garmin introduced the G2000 PRIME, a new integrated flight deck designed for high-performance Class I/II piston and electric aircraft. It features large, edge-to-edge touchscreen displays with advanced multi-touch capabilities, faster processors, and...
UniFirst Corporation has been recognized on Selling Power's 60 Best Companies to Sell For list for the 23rd consecutive year, highlighting its strong sales culture and support for sales professionals. The list evaluates companies on compensation, tra...
The global Reactive Hot Melt Adhesives market is projected to grow from USD 2.02 billion in 2025 to USD 4.29 billion by 2035, at a CAGR of 7.72%. Growth is fueled by regulations limiting solvent adhesives, increased use of polyurethane adhesives in a...
Montero Mining completed drillhole MON-ELV-02 to 625.25 meters at its Elvira Gold Project in Chile, successfully testing its top exploration target. The hole confirmed predicted volcanic and porphyry sequences with extensive pyrite and high-sulphidat...
